MannKind | MNKD - Cash And Equivalent


MannKind reported $52.93M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Adma Biologics USD 136.02M 2.13M Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Insmed USD 544.76M 37.42M Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
MacroGenics USD 113.91M 47.39M Jun/2026
MannKind USD 52.93M 95K Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Novavax USD 191.46M 36.9M Jun/2026
Novo Nordisk DKK 21.13B 17.81B Mar/2026
Pfizer USD 976M 727M Jun/2026
Sanofi EUR 6.35B 806M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026